Figure 2
From: The Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) trial
Relative risks of death in NYHA class IV patients from all causes according to trial. Horizontal lines, 95% confidence intervals.
Figure 2 | Current Controlled Trials in Cardiovascular Medicine
